Solasia Pharma K.K. (4597.T)
JPY 42.0
(2.44%)
JPY 42.0
(2.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -635 Million JPY | 67.06% |
| 2022 | -1.94 Billion JPY | -0.83% |
| 2021 | -1.92 Billion JPY | 46.85% |
| 2020 | -3.61 Billion JPY | -181.27% |
| 2019 | -1.28 Billion JPY | 43.23% |
| 2018 | -2.26 Billion JPY | -124.68% |
| 2017 | -1 Billion JPY | -118.99% |
| 2016 | -460.75 Million JPY | 34.3% |
| 2015 | -701.31 Million JPY | 0.02% |
| 2014 | -701.48 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -215 Million JPY | 5.7% |
| 2024 Q2 | -269 Million JPY | -25.12% |
| 2023 Q4 | -230 Million JPY | -15.0% |
| 2023 Q1 | -121 Million JPY | 67.73% |
| 2023 Q2 | -77 Million JPY | 36.36% |
| 2023 Q3 | -200 Million JPY | -159.74% |
| 2023 FY | - JPY | 67.06% |
| 2022 Q3 | -586 Million JPY | -16.73% |
| 2022 Q1 | -476 Million JPY | -105.17% |
| 2022 FY | - JPY | -0.83% |
| 2022 Q4 | -375 Million JPY | 36.01% |
| 2022 Q2 | -502 Million JPY | -5.46% |
| 2021 Q3 | -576 Million JPY | 3.36% |
| 2021 FY | - JPY | 46.85% |
| 2021 Q1 | -519 Million JPY | 75.18% |
| 2021 Q2 | -596 Million JPY | -14.84% |
| 2021 Q4 | -232 Million JPY | 59.72% |
| 2020 Q2 | -610 Million JPY | -49.88% |
| 2020 Q3 | -510 Million JPY | 16.39% |
| 2020 FY | - JPY | -181.27% |
| 2020 Q1 | -407 Million JPY | -730.61% |
| 2020 Q4 | -2.09 Billion JPY | -310.0% |
| 2019 Q3 | -452 Million JPY | -12.44% |
| 2019 Q1 | -383 Million JPY | 51.02% |
| 2019 FY | - JPY | 43.23% |
| 2019 Q4 | -49 Million JPY | 89.16% |
| 2019 Q2 | -402 Million JPY | -4.96% |
| 2018 Q4 | -782 Million JPY | -36.0% |
| 2018 Q3 | -575 Million JPY | 2.04% |
| 2018 Q2 | -587 Million JPY | -82.3% |
| 2018 Q1 | -322 Million JPY | 44.96% |
| 2018 FY | - JPY | -124.68% |
| 2017 Q1 | -243.1 Million JPY | -4091.38% |
| 2017 Q2 | -309.61 Million JPY | -27.36% |
| 2017 Q3 | 128.79 Million JPY | 141.6% |
| 2017 FY | - JPY | -118.99% |
| 2017 Q4 | -585.05 Million JPY | -554.26% |
| 2016 Q4 | -5.8 Million JPY | 97.12% |
| 2016 FY | - JPY | 34.3% |
| 2016 Q3 | -201.34 Million JPY | -1.11% |
| 2016 Q2 | -199.13 Million JPY | -265.6% |
| 2016 Q1 | -54.46 Million JPY | 77.99% |
| 2015 Q3 | -211.47 Million JPY | 0.0% |
| 2015 Q4 | -247.49 Million JPY | -17.03% |
| 2015 FY | - JPY | 0.02% |
| 2014 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 110.546% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 100.073% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 99.774% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 100.34% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | 211.214% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 101.75% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 105.176% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 100.616% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | 149.111% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 103.462% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 107.077% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 117.302% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 145.26% |
| Tsumura & Co. | 30.77 Billion JPY | 102.064% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 103.392% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 112.047% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 101.787% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 109.227% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 103.624% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 106.167% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 83.067% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 108.407% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 11.064% |
| MedRx Co., Ltd | -884.51 Million JPY | 28.209% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 111.47% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 73.251% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 106.93% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 101.722% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | -17.966% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 102.457% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 112.447% |